

Recombinant Human I-309 (CCL1)

Alternate names:	CCL1, I309, TCA3
Catalog No.:	PA1151X
Quantity:	10 µg
Concentration:	1 mg/ml
Species:	Human
Source:	E. coli, E.coli
Format:	State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >99% Greater than 99.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. Buffer System: Human I-309 was lyophilized from a concentrated sterile solution containing no additives. Endotoxin Level: Less than 0.1 ng/µg (IEU/µg) of Human HCC-1. Dimers: Less than 1% as determined by silver-stained SDS-PAGE gel analysis. Reconstitution: It is recommended to reconstitute the lyophilized Human I-309 in sterile 18MO-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Description:	Recombinant Human I-309 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 74 amino acids. Human I-309 is purified by proprietary chromatographic techniques. AA Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Lys-Ser-Met-Gln. Biological Activity: Human I-309 is fully biologically active when compared to standard. The Biological activity is calculated by its ability to chemoattract human T cells at 10.0-100.0 ng/ml. Molecular weight: 8504 Dalton. Molecular weight: 9 kDa
Add. Information:	Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm . 2. Analysis by RP-HPLC, using a calibrated solution of Human I-309 as a Reference Standard.
Storage:	Lyophilized I-309 although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution Human I-309 should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

General Readings:

1. Gilchrest H, Cheewatrakoolpong B, Billah M, Egan RW, Anthes JC, Greenfeder S. Human cord blood-derived mast cells synthesize and release I-309 in response to IgE. *Life Sci.* 2003 Oct 3;73(20):2571-81. PubMed PMID: 12967681.
2. Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, et al. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. *Eur J Immunol.* 2003 Feb;33(2):494-501. PubMed PMID: 12645948.
3. Ruckes T, Saul D, Van Snick J, Hermine O, Grassmann R. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. *Blood.* 2001 Aug 15;98(4):1150-9. PubMed PMID: 11493464.
4. Inngjerdigen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. *J Immunol.* 2000 Apr 15;164(8):4048-54. PubMed PMID: 10754297.
5. Haque NS, Fallon JT, Taubman MB, Harpel PC. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. *Blood.* 2001 Jan 1;97(1):39-45. PubMed PMID: 11133740.
6. Bernardini G, Spinetti G, Ribatti D, Camarda G, Morbidelli L, Ziche M, et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. *Blood.* 2000 Dec 15;96(13):4039-45. PubMed PMID: 11110671.

Pictures:

PA1151XME0607

